ScreenerHero
ANIPANI Pharmaceuticals, Inc.
NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · anipharmaceuticals.com
77.56USD-0.59%Mkt Cap: 1.79B $P/E: 17.00

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap1.79B $
Enterprise Value1.91B $
Revenue (TTM)978.38M $
Gross Profit542.06M $
Net Income (TTM)78.34M $
Revenue/Share47.24 USD
Last Price77.56 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees970
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS00182C1036
Valuation
P/E (Trailing)17.00
P/E (Forward)7.34
PEG—
EV/EBITDA9.10
EV/Revenue1.95
P/S1.82
P/B2.77
EPS (TTM)4.55
EPS (Forward)10.54
52W Range
70.1525% of range99.50
52W High99.50 USD
52W Low70.15 USD
Profitability
Gross Margin61.36%
Oper. Margin14.97%
EBITDA Margin21.40%
Profit Margin8.87%
ROE14.49%
ROA5.44%
Growth
Revenue Growth25.90%
Earnings Growth191.10%
Cash Flow & Leverage
Operating CF185.22M $
CapEx (TTM)34.32M $
FCF Margin13.51%
FCF Yield7.38%
Net Debt249.07M $
Net Debt/EBITDA1.19
Balance Sheet
Debt/Equity1.14
Current Ratio2.91
Quick Ratio2.30
Book Value/Sh27.87 USD
Cash/Share17.59 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:6
Split DateJul 18, 2013
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)108.38 USD
Upside (mean)+39.7%
Target Range90.00 USD – 121.00 USD
$90.00+39.7% to mean$121.00
# Analysts8
Ownership
Shares Out.22.96M
Float19.65M
Insiders5.45%
Institutions107.21%
Short Interest
Short Ratio8.4d
Short % Float12.38%
Short % Out.10.16%
Shares Short2.33M
Short (prev mo.)3.44M
Technical
SMA 5080.44 (-3.6%)
SMA 20080.17 (-3.3%)
Beta0.46
S&P 52W Chg18.16%
Avg Vol (30d)322.32K
Avg Vol (10d)420.34K
Technical Indicators
RSI (14)48.4
MACD-1.2198
MACD Signal-1.0890
MACD Hist.-0.1308
BB Upper82.92 USD
BB Middle78.27 USD
BB Lower73.62 USD
BB Width11.89%
ATR (14)2.802 USD
Vol Ratio (20d)0.69x